Bicara Therapeutics Files 8-K with Q4 2025 Results
Ticker: BCAX · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0002023658
| Field | Detail |
|---|---|
| Company | Bicara Therapeutics Inc. (BCAX) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, financial-results, 8-k
TL;DR
Bicara Therapeutics dropped its Q4 2025 earnings report on 8-K.
AI Summary
Bicara Therapeutics Inc. filed an 8-K on March 30, 2026, reporting its financial results for the period ending March 30, 2026. The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), with a press release for Q4 2025 attached as an exhibit.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Bicara Therapeutics, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.
Key Players & Entities
- Bicara Therapeutics Inc. (company) — Filer of the 8-K
- 0002023658 (company) — CIK number for Bicara Therapeutics Inc.
- 2026-03-30 (date) — Filing date and period of report
- Q4 2025 (date) — Period covered by the press release exhibit
FAQ
What specific financial results are detailed in the press release?
The filing indicates a press release for Q4 2025 is included as Exhibit 99.1, which would contain the specific financial results.
What is the CIK number for Bicara Therapeutics Inc.?
The CIK number for Bicara Therapeutics Inc. is 0002023658.
When was this 8-K filing accepted by the SEC?
The filing was accepted on 2026-03-30 at 07:47:00.
What items are covered in this 8-K filing?
This 8-K covers Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
Where is Bicara Therapeutics Inc. headquartered?
Bicara Therapeutics Inc.'s mailing and business address is 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2026-03-30 07:47:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BCAX The Nasdaq Global Mark
Filing Documents
- bcax-20260330.htm (8-K) — 27KB
- pressrelease-q42025.htm (EX-99.1) — 99KB
- bicaralogo.jpg (GRAPHIC) — 7KB
- 0001628280-26-021868.txt ( ) — 266KB
- bcax-20260330.xsd (EX-101.SCH) — 2KB
- bcax-20260330_lab.xml (EX-101.LAB) — 23KB
- bcax-20260330_pre.xml (EX-101.PRE) — 13KB
- bcax-20260330_htm.xml (XML) — 3KB
02 - Results of Operations and Financial Condition
Item 2.02 - Results of Operations and Financial Condition. On March 30, 2026, Bicara Therapeutics Inc. (the "Company") issued a press release announcing its financial results and business highlights for the fiscal year and quarter ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release of Bicara Therapeutics Inc. , dated March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 30th day of March, 2026. Bicara Therapeutics Inc. By: /s/ Claire Mazumdar Name: Claire Mazumdar Title: Chief Executive Officer